{"entity":{"id":"nct05297890","kind":"trial","name":"A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Lorlatinib in non-small-cell lung cancer and small-cell lung cancer, run by CStone Pharmaceuticals, active and no longer recruiting.","summary":"A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05297890 by CStone Pharmaceuticals, with 70 participants enrolled, started 2022-05-27 and due to reach its primary completion in 2023-12-26. Interventions recorded: Lorlatinib. Conditions listed: Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05297890","url":"https://clinicaltrials.gov/study/NCT05297890"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["lorlatinib"],"companies":["cstone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05297890","phase":"2","setting":"A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer Subjects in China","sponsor":"CStone Pharmaceuticals","enrolled":70,"outcomes":[]},"route":"/trials/nct05297890/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/"}],"company":[{"id":"cstone","kind":"company","name":"CStone Pharmaceuticals","route":"/companies/cstone/"}]}}